Valuation of Biosimilar and Key Value Drivers 02...
Transcript of Valuation of Biosimilar and Key Value Drivers 02...
![Page 1: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/1.jpg)
www.venturevaluation.com
Dr. Patrik FreiOctober 2015 | Biosimilars Asia
Valuation of Biosimilar and Key Value Drivers
![Page 2: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/2.jpg)
www.venturevaluation.com
Agenda
• Introduction
• Valuation of Biosimilar
• Key Value Driver / Conclusion
2
![Page 3: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/3.jpg)
www.venturevaluation.com
- Switzerland (HQ); Canada; UK; Singapore; India; China
- Global experience with 25 people
- Track record of over 350 valued companies / products
- Investor clients such as Novartis, GSK, Fraunhofer Gesellschaft, European Investment Bank; Company clients: Arpida/Evolva; 4SC;
- Product valuation for licensing deals
Independent assessment and valuation of Life Sciences companies / therapeutic products
Company, Deals & Investors Database -Biotechgate.com
Venture Valuation
3
![Page 4: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/4.jpg)
www.venturevaluation.com
4
Valuation of Biosimilar
Company Country OwnershipRaised* m USD
Market Cap. USD
3S Bio (3SBio) Inc. China Public (IPO 2015) 92 2.8Bn
Coherus Biosciences, Inc. USA Public (IPO 2014) 214 1.0Bn
BeiGene (Beijing) Co., Ltd China Private 172
XBiotech Inc. USA Public (IPO 2015) 76 451.6M
Momenta Pharmaceuticals USA Public (IPO 2004) 57 1.1Bn
Oncobiologics, Inc. USA Private 31
FINOX Biotech SwitzerlandPrivate 24
* Raised in last 3 years Source: Biotechgate.com
![Page 5: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/5.jpg)
www.venturevaluation.com
5
rNPV Product Valuation
Development MarketPhase
Ca
sh
Flo
w
Time
1. Development phase => investment
Risk (r) => success rate
2. Market phase => revenues
Patent expiry => end of revenues
(often no terminal value)
3. Discount / WACC => non-specific risk
![Page 6: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/6.jpg)
www.venturevaluation.com
6
Five Step Process
Determine Cash Flows in Development Phase
Determine Cash Flows in Market Phase
Discount with Discount rate
Adjust for Risk
Sum discounted cash flows$$$$$5
1Devel.
2Market
3Discount rate
4Risk
![Page 7: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/7.jpg)
www.venturevaluation.com
7
rNPV – Example
- Phase I product
- 15% discount rate
- 11% Probability of success (p1 to market)
⇒CF: USD 2’182m
⇒DCF: USD 216m
⇒ rNPV: USD 10m
-50'000
-
50'000
100'000
150'000
200'000
250'000
300'000
350'000
400'000
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Cash Flow
Discounted CF
rNPV
-10'000
-5'000
-
5'000
10'000
15'000
20'000
25'000
30'000
35'000
40'000
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Discounted CF
rNPV
![Page 8: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/8.jpg)
www.venturevaluation.com
Agenda
• Introduction
• Valuation of Biosimilar
• Key Value Driver / Conclusion
8
![Page 9: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/9.jpg)
www.venturevaluation.com
9
Development Phase
Innovative Biologics
• Determine cost and duration of clinical trials
• Manufacturing
• Regulatory affairs
• Long term animal tox. studies
Biosimilar
• Shorter development timelines / costs
• Finding patients for clinical trials
• Comparative trials => cost for original
product$$$$$5
1Devel.
2Market
3Discount rate
4Risk
![Page 10: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/10.jpg)
www.venturevaluation.com
10
Cost and Lead Times
$$$$$5
1Devel.
2Market
3Discount rate
4Risk
USD -+1bn
USD 60 –200m
Source: Bernstein Research
Source: Hospira
![Page 11: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/11.jpg)
www.venturevaluation.com
11
$$$$$5
1Devel.
2Market
3Discount rate
Reduce time to market
4Risk
Original product Biosimilar
Phase I 12 month / 4m 12 month / 2 m
Phase II 36 month / 20m n/a
Phase III 36 month / 120m 36 month / 60m
Approval 12 month / 8m 12 month / 6m
Total 8 years / 152m 5 years / 68m
rNPV USD 10m USD 40m
![Page 12: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/12.jpg)
www.venturevaluation.com
12
Market Phase
$$$$$5
1Devel.
2Market
3Discount rate
Develop assumptions to predict the
future market
Methods used:• Bottom-up approach
- Based on primary market data
• Top-down approach
- based on comparable products4Risk
![Page 13: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/13.jpg)
www.venturevaluation.com
13
Market Phase
$$$$$5
1Devel.
2Market
3Discount rate
Biosimilar:
- Different adaption of Biosimilar (EU / US; Germany vs. rest of Europe)
- Uncertainty in future (reimbursement, incentives)
- Average price cut of 30%
- More patients? (price elasticity)
- Different penetration (commodity vs. differentiation)
- Competition (original product / biosimilar / biobetter)
=> Market share?
4Risk
Development MarketPhase
Ca
sh
Flo
w
Time
Original
Biosimilar
![Page 14: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/14.jpg)
www.venturevaluation.com
14
Market Phase
$$$$$5
1Devel.
2Market
3Discount rate
Market share:
4Risk
Global Sales Avastin 2014 7'400
Reduction in pricing 30% 5'180
Increase in reach due to lower prices 15% 5'957
Target indication (Colorectal cancer, NSCLC) 80% 4'750
Competion new therapies 74% 3'515
Competition
Originator market share 55% = 1'940
First to market Amgen 13% = 471
Phase III (2) probability adjusted 9% = 313
Phase I (3) probability adjusted 7% = 251
Pre-clinical (5) probability adjusted 11% = 376
Product to be valued (phase I) 5% = 164
Total 100% 3'515
![Page 15: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/15.jpg)
www.venturevaluation.com
15
$$$$$5
1Devel.
2Market
3Discount rate
Reduced market
4Risk
Original product Biosimilar
Peak sales
(2031)USD 983m USD 164m
Life CycleDrop of sales after
patent expiryGrowth of 3% per year
rNPV USD 10 m USD -13m
![Page 16: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/16.jpg)
www.venturevaluation.com
16
Discount rate
$$$$$5
1Devel.
2Market
3Discount rate
4Risk
Cost of Equity / discount rate in rNPV:
• Early stage 12% - 28%
• Mid stage 10% - 22%
• Late stage 9% - 20%
• Pharma below 10% (incl. debt)Source. www.biostrat.dk
Cost of equity and non-development
associated risks.
![Page 17: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/17.jpg)
www.venturevaluation.com
17
Discount rate
Used discount rate in rNPV:
• Biosimilar player => lower WACC;
• Generally higher uncertainty (+)
$$$$$5
1Devel.
2Market
3Discount rate
4Risk
15% => USD 10m
18% => USD 2m
12% => USD 22m
![Page 18: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/18.jpg)
www.venturevaluation.com
18
$$$$$5
1Devel.
2Market
3Discount rate
Adjust for risk (I)
4Risk
Source: Nature Biotechnology; Clinical development success rates for investigational drugs; January 2014
![Page 19: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/19.jpg)
www.venturevaluation.com
19
Adjust for Risk (III)
$$$$$5
2Market
3Discount rate
4Risk
1Devel.
The relation between Risk and Value
• Completion of a phase Direct value increase
Va
lue
Phase I Phase II NDA/BLAPhase III Approval/Market
64%
86%
61%
32%
Cumulative Sucess rate: 11%
889
649
167
2410
889
649
167
9549
Original Biosimilar
![Page 20: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/20.jpg)
www.venturevaluation.com
20
$$$$$5
1Devel.
2Market
3Discount rate
Adjust for risk (I)
4Risk
Used risk adjustment in rNPV:
• Biosimilar => lower risk (-)
• No phase II
• Individual adjustment
Original product Biosimilar
Phase I 64% 64%
Phase IIa/IIb 60% / 55% 100%
Phase III 61% 61%
Approval 86% 86%
Cum. Success 11% 33%
rNPV USD 10m USD 49m
![Page 21: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/21.jpg)
www.venturevaluation.com
21
$$$$$5
1Devel.
2Market
3Discount rate
Summary
4Risk
Original product Biosimilar
Costs 152m 68m
Time to market 8 years 5 years
Sales 2031 USD 983m USD 164m
Cum. Success 11% 33%
rNPV USD 10m USD 13m
rNPV after
phase IIIUSD 649m USD 179m
![Page 22: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/22.jpg)
www.venturevaluation.com
Agenda
• Introduction
• Valuation of Biosimilar
• Key Value Driver / Conclusion
22
![Page 23: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/23.jpg)
www.venturevaluation.com
23
Key Value Driver
Strategic decision to maximize value
• Value drivers are same as innovative drugs
• Variation on
� Timeline (+)
� Development costs (+)
� Market (-)� Competition� Pricing� Accessible market
� Attrition rate (+)
� Discount rate (+/-)
=> Market / Competition / Pricing as high impact
![Page 24: Valuation of Biosimilar and Key Value Drivers 02 (pfr)resourcecenter.venturevaluation.com/wp-content/upload… · · 2015-11-06 Dr. Patrik Frei October 2015 | Biosimilars Asia Valuation](https://reader031.fdocuments.net/reader031/viewer/2022022515/5af8d2427f8b9a44658ce94d/html5/thumbnails/24.jpg)
www.venturevaluation.com
Thank you for listening!
Slides available on www.venturevaluation.com => resource center
Tel.: +41 43 321 8660 Venture Valuationwww.venturevaluation.com Switzerland / [email protected]